Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study

Size: px
Start display at page:

Download "Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study"

Transcription

1 Respiratory Medicine (2003) 97, Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study Karin H. Groenewegen, Emiel F.M. Wouters* Department of Pulmonology, University Hospital Maastricht, P.O. Box 5800, Maastricht 6202 AZ, The Netherlands KEYWORDS Chronic obstructive pulmonary disease; Acute exacerbations; Bacterial infections Summary Study objective: To investigate the frequency of respiratory bacterial infections in hospitalized patients, admitted with an acute exacerbation of chronic obstructive pulmonary disease (COPD), to identify the responsible pathogens by sputum culture and to assess patient characteristics in relation to sputum culture results. Methods: We prospectively evaluated clinical data and sputum culture results of 171 patients, admitted to the pulmonology department of the University Hospital Maastricht with an acute exacerbation of COPD from 1st January 1999 until 31st December Results: Eighty-five patients (50%) had positive sputum cultures, indicating the presence of bacterial infection. Pathogens most frequently isolated were: Haemophilus influenzae (45%), Streptococcus pneumoniae (27%), and Pseudomonas aeruginosa (15%). Patients with more severely compromised lung function had a higher incidence of bacterial infections (P ¼ 0:026). There were no significant differences in age, lung function parameters, blood gas results and length of hospital stay between patients with and without bacterial infection. There were no correlations between the type of bacteria isolated and clinical characteristics. Conclusion: Incidence of bacterial infection during acute exacerbations of COPD is about 50%. Patients with and without bacterial infection are not different in clinical characteristics or in outcome parameters. Patients with lower FEV 1 have a higher incidence of bacterial infections, but there is no difference in the type of bacterial infection. In the future, the pathogenic role of bacterial infection in exacerbations of COPD should be further investigated, especially the role of bacterial infection in relation to local and systemic inflammation. r 2003 Elsevier Science Ltd. All rights reserved. Introduction Chronic obstructive pulmonary disease (COPD) comprises a heterogeneous group of conditions, characterized by varying degrees of expiratory flow limitation. Exacerbations punctuate the clinical course of COPD in many patients. These episodes of acute exacerbation can vary considerably in *Corresponding author. Tel.: þ ; fax: þ address: ewo@slon.azm.nl (E.F.M. Wouters). severity: part of the exacerbations will remain unreported while some episodes require hospital admission. Hospital admission for acute exacerbations forms the major component of the economical burden of COPD in western countries. 1 These exacerbations are characterized by varying combinations of symptoms as increase in cough, sputum production, worsening of dyspnea or changes in sputum purulence. Recent studies have indicated that health status of patients with COPD has been influenced by the presence and frequency of these acute /03/$ - see front matter r 2003 Elsevier Science Ltd. All rights reserved. doi: /s (03)00026-x

2 Bacterial Infections in patients 771 exacerbations. 2,3 The exact role of periods of acute exacerbations in the pathogenesis of COPD remains unclear, especially the relationship between bronchial inflammation and lung defense during these possible noxious events. 4 Some studies have indicated that recurrent exacerbations may be associated with increased airway inflammation, although many factors may influence the state of inflammation in the airways. 5 Recent data also suggest the presence of decreased antiproteinase activity in sputum of patients with recurrent exacerbations. 4 Exacerbations are not only heterogeneous in severity and symptom characteristics but are also in nature. Although several events may lead to acute exacerbations, respiratory tract infections are often considered as the initiating event contributing to the deterioration in the clinical condition. Especially, the role of bacterial infections and the value of antibiotic therapy have been a matter of debate for many decades. 6 8 An important problem in defining the role of bacteria in these episodes of acute exacerbation is the bacterial colonization of the lower airways even in the absence of symptoms of an exacerbation. 7 Careful investigations have reported the presence of bacterial pathogens in only about 50% of exacerbations However, these studies have been performed in different populations of COPD patients, and most frequently in outpatients. Recently, two studies have investigated the type of bacterial pathogens isolated in sputum of COPD patients, hospitalized for an acute exacerbation. 12,13 In these studies a correlation was found between lung function and the type of bacteria isolated: patients with more compromised lung function had a higher incidence of infections with Pseudomonas aeruginosa and other Gram-negative bacteria isolated from their sputum. These findings suggested that patients with more advanced lung disease may need a different pharmacological therapy than patients with milder disease. The generalization of these findings as well as the interpretation of them as disease-specific findings are hampered by limited availability of data on distribution of bacterial flora in COPD patients from different geographical areas as qualitative differences in bacterial flora can be related to many other factors. Therefore, it seems interesting to investigate prospectively the prevalence of acute bacterial infections during these episodes of hospital admission as well as if specific patient profiles are related to a different pattern of microorganisms in patients admitted for an acute exacerbation of the disease. Furthermore, we questioned if the presence of bacterial infection influences the clinical outcome of hospital admissions for acute exacerbations. Material and methods Study population and study design All patients, admitted with an acute exacerbation of COPD to the pulmonology ward of the University Hospital Maastricht, between 1st January 1999 and 31st December 1999, were prospectively evaluated. All patients were diagnosed as having COPD, according to the criteria of the American Thoracic Society. 16 Acute exacerbation was defined by the presence of an increase in at least two of the three following symptoms: dyspnea, cough and sputum purulence. Admission to the hospital was deemed necessary based on the clinical situation of the patient or the presence of complicating factors as respiratory failure. In all cases, the need for admission was decided by a senior chest physician, experienced in the management of COPD patients. Chest X-rays were performed in each patient on admission and patients with lobar infiltrates or radiologic signs of pneumonia on chest X-ray were excluded from the study. Patients were included only once in the study even if hospitalized more frequently. For all included patients the following data were assessed: medical history, lung function measurements, blood gases, duration of hospital stay, previous treatment, chronic corticosteroid use and results of sputum cultures. Medical history, previous treatment and use of corticosteroids were recorded from the patients charts on standardized forms. Chronic use of oral corticosteroids was defined as the use of daily oral corticosteroids for at least 1 year in a dosage of at least 5 mg Prednisolone or equivalent. On admission, arterial blood gases at rest were assessed by puncture of the radial artery during room air breathing. Patients were discharged from the pulmonary ward by decision of a senior chest physician, unaware of the goals of the present study. Total duration of hospital stay was recorded, counting from the first day of admission before 0.00 h until the day of discharge. Patients were treated with a standard protocol consisting of intravenous administration of corticosteroids and theophylline and nebulization of salbutamol and ipratropiumbromide as bronchodilating agents. O 2 was titrated by follow-up of blood gas values as well as continuous monitoring of

3 772 K.H. Groenewegen, E.F.M. Wouters oxygen saturation. Antibiotics were not prescribed until the results of the sputum cultures were available, unless the clinical condition of the patient necessitated early intervention based on documented resistance pattern of isolated microorganisms. Lung function data Spirometries were performed daily during admission for the exacerbation. Spirometries were performed using the portable pneumotachograph from Jaeger pulmonary function equipment (W-.urzburg, Germany). The value after recovery, prior to discharge from the hospital was used in the analyses. Based on the ATS criteria, 16 lung function was rated in three stages of severity: stage I: FEV 1 of X50% predicted, stage II: FEV 1 between 35% and 50% predicted, stage III: FEV 1 p35% predicted. At least one sample of spontaneously expectorated sputum for microbiologic evaluation was obtained in all patients during admission. This is part of a common medical practice in our hospital for patients admitted for an acute exacerbation, and also it is recommend in the recently published GOLD guidelines for the management of COPD. 17 Samples were collected in sterile sputum cups and sent to the laboratory within 1 h after expectoration. A Gram stain of the sputum in the area of maximal purulence was examined for polymorphonuclear leukocytes and epithelial cells. The number of leukocytes was semiquantitatively described as: none, sporadic, few, moderate or many. A sputum sample was considered representative if many leukocytes were present in the absence of epithelial cells. Another portion of a documented purulent material was used for microbiological analysis. Sputa were processed according to standard microbiological methods. 18 A sputum culture was considered as positive (proving bacterial infection) if significant bacterial growth was present as defined by the number of bacteria (higher than 10 5 colony forming units ¼ cfu) in a representative sample. Identified bacteria were classified into three groups: group 1 included Haemophilus influenzae and Moraxella catarrhalis, group 2 included Streptococcus pneumoniae and other Gram-positive cocci and group 3 included Pseudomonas and other Gram-negative microorganisms. Other identified bacteria are considered non-pathogenic microorganisms (NPMs), belonging to the oropharyngeal or gastrointestinal flora. A microbial resistance pattern was available for all pathogens. For all pathogens resistance patterns were determined for Amoxicillin, Amoxicillin/Clavulanic acid, Doxycyclin and Co-trimoxazole. In case of isolation of Pseudomonas and other Gramnegative species resistance patterns to Gentamycin, Piperacillin, Ciprofloxacine, Ofloxacine and Cefuroxim were determined additionally. Statistical analysis The statistical analyses were performed using the Statistical Products and Service Solutions (SPSS; Chicago, IL, USA) for Windows Package. Groups were compared by analysis of variance (ANOVA). The w 2 test was used to compare categorical variables. Results are presented as mean7sd unless stated otherwise. Sputum cultures Results Patient characteristics Between 1st January 1999 and 31st December patients were included with acute exacerbation of COPD. Characteristics of the study population are summarized in Table 1. Most patients were elderly with severely impaired lung function (mean FEV 1 was 0.84 l or 34.6% predicted). Hypoxia as well as hypercapnia were very common findings on admission; 141 ( ¼ 85%) of the patients had arterial oxygen tension o8.7 kpa, arterial carbon dioxide tension higher than 5.9 kpa was measured in 93 patients ( ¼ 55%). Sixty-three patients ( ¼ 37%) had been treated with antibiotics prior to admission to the hospital. Prescribed antibiotics by general practitioners were: Doxycycline (37%), Amoxicillin (21%), Amoxicillin/Clavulanic acid (29%) and Azithromycine (10%). Information concerning the remaining 3% could not be retrieved. Forty-three percent of the patients had also received a boost of oral corticosteroids prior to admission. Mean hospital stay was 11.7 days and median hospital stay was 10 days. Thirteen patients died during their hospital stay, resulting in an in-hospital mortality of 8%. Seventeen patients were admitted to ICU because of progressive respiratory failure: In 15 patients failure of conservative treatment in the first 48 h necessitated referral to the ICU; in two patients clinical condition deteriorated after initial

4 Bacterial Infections in patients 773 Table 1 Clinical characteristics of the COPD population and the patients with and without bacterial infection Whole group (n ¼ 171) Negative sputum culture (n ¼ 86) Positive sputum culture (n ¼ 85) Age (years) FEV 1 (l, % pred) NS PaO 2 (kpa) NS PaCO 2 (kpa) NS Hospital stay (days) NS Sex (M/F) 104/67 50/36 54/31 NS Pretreatment with antibiotics (y/n) 63/108 30/56 33/52 NS Pretreatment with corticosteroids (y/n) 73/98 29/57 31/54 NS Chronic corticosteroids (y/n) 17/154 8/78 9/76 NS ICU admission (y/n) 17/154 10/76 7/78 NS Died during admission (y/n) 13/158 6/80 7/77 NS P-value improvement. Intubation and mechanical ventilation was necessary in 10 patients, four patients received non-invasive ventilation (BiPAP) and in three patients conservative treatment could be continued under close supervision. Patients transferred to ICU had a longer duration of hospital stay (P ¼ 0:005; mean 17.3 days, median 15 days). One patient died during ICU admission (6%). Percent Microbiological analysis Sputum cultures could be obtained in 142 patients ( ¼ 83%). Other patients were unable to expectorate sputum spontaneously during hospitalization. Samples were considered not representative based on microbiological criteria in 54 cases. In 85 of the 88 representative samples (97%) a significant bacterial growth was reported; in 61 samples (72%) there was growth of one single species in significant concentrations, in 22 samples (26%) there was growth of two different species in significant concentrations and in four samples (5%) growth of three different species in significant concentrations was present. The most frequently isolated species were H influenzae (23 cases as single pathogen, 15 cases in combination with other pathogens, overall 38/85 cases or 45%) and S. pneumoniae (nine cases as single pathogen, 15 cases in combination with other pathogens, overall 24/85 cases or 28%). P. aeruginosa was isolated in 13/85 cases (15%). Other bacteria isolated were: M. catarrhalis (three cases as single pathogen, two cases in combination, overall 5/85 cases or 6%), and Klebsiella pneumoniae (one case as single pathogen, three cases in combination, overall 4/85 cases or 5%). In 14/85 0 NPM's others H. infl. and P.aeru H. infl. and S. pneu Klebsiella M.catarrhalis P.aeruginosa S.pneumoniae H.influenzae Fig. 1 Types of isolated microorganisms found during acute exacerbations of COPD. cases (16%) NPMs were found. These data are schematically presented in Fig. 1. No resistant strains of S. pneumoniae to Amoxicillin were isolated. For H. influenzae as well as for M. catarrhalis two b-lactamase producing strains were identified. No resistant Pseudomonas strains were isolated in the studied population. No significant differences were found in mean FEV 1, PaO 2 and PaCO 2 between the patients with and without positive sputum culture (Table 1). A course of antibiotics or a boost of corticosteroids, prescribed prior to admission, did not influence the outcome of sputum cultures. 52.4% who had received antibiotics and 51.7% of patients who had received a boost of corticosteroids prior to admission had bacterial infection.

5 774 K.H. Groenewegen, E.F.M. Wouters No difference in duration of hospitalization could be demonstrated between patients with and without bacterial infection on admission. In the group of patients with positive sputum culture (n ¼ 85), 10 patients were transferred to ICU of whom five patients were intubated for mechanical ventilation, while in the negative sputum culture group (n ¼ 86) seven patients were transferred to ICU of whom four required mechanical ventilation. Admission to ICU was not related to the presence and type of bacterial infection during exacerbation. In comparison of patients with Pseudomonas infection to those with H. influenzae or S. pneumoniae infections, it was demonstrated that the former group was significantly older; other parameters were not different between these groups. Lung function parameters Based on lung function data obtained prior to discharge from the hospital, marked airflow obstruction was present in the majority of the patients: 81 patients (47%) had severe COPD 55 patients (32%) had moderate COPD and 22 patients (13%) had mild COPD, according to ATS staging. In 12 patients, no spirometric data could be obtained during hospital stay. Ten patients had an established diagnosis of severe COPD based on clinical records. In two patients, the diagnosis of COPD was established on clinical grounds and the information regarding medical history as obtained by their general practitioner (Fig. 2). The incidence of bacterial infection was significantly related to the degree of airflow limitation Percent Fig. 2 group 1 group 2 group 3 p = 0.08 between severe and moderate COPD p = between severe and mild COPD FEV1 >35 % <= 35% Positive sputum cultures after stratification. % of patients with bacterial infection (Fig. 3): patients with severe COPD had significantly more bacterial infections than patients classified as moderate (P ¼ 0:015) or mild COPD (P ¼ 0:08). However, the type of bacteria isolated was not related to the degree of airflow limitation (Fig. 3). Discussion FEV % FEV % FEV1 < 35 % group of micro-organism group 1 = H. influenza and M. catharralis group 2 = S.pneumoniae and other Grampositive cocci group 3 = Pseudomonas aeruginosa and other Gramnegative micro-organisms Fig. 3 Distribution of groups of bacteria isolated according to FEV 1 impairment. The present study confirms previous data reporting a higher incidence of bacterial infections in patients with a severe impairment in lung function during hospital admissions for acute exacerbations. However, no relationship between the type of bacteria isolated and the degree of lung function impairment could be demonstrated. The presence of bacterial pathogens was found in 50% of all admitted patients. No differences in clinical characteristics could be demonstrated between patients with and without isolation of bacterial pathogens neither with the type of bacterial pathogens. Microorganisms most frequently isolated were H. influenzae (45%) and S. pneumoniae (27%). Other pathogens isolated were P. aeruginosa (15%), M. catarrhalis (6%) and K. pneumoniae (5%). The presence of bacterial pathogens did not influence the clinical outcome defined by the length of hospital stay and the need for ICU admission. One of the most important findings in the present study is the relation between the occurrence of bacterial infections and the degree of airflow

6 Bacterial Infections in patients 775 limitation: patients with a lower FEV 1 had a higher incidence of bacterial infection. This is in line with previous studies on the prevalence of bacteria in stable COPD patients. 8 However, opposite to previously reported data we found no shift in the type of microorganism isolated in patients with more severely compromised lung function. 12,13 Indeed, both Eller and Miravitlles reported in patients with lower FEV 1 a higher incidence of Pseudomonas and Enterobacteriacae in their sputum. They hypothesized a possible relationship between the decline in lung function and occurrence of Pseudomonas and other Gram-negative species in sputum. Our data were even obtained in patients with more severely compromised lung function. The incidence of Pseudomonas infections in our study was comparable with the data reported by Miravitlles, but markedly lower than in the study of Eller. Further data with more specific characterization of the patients suffering from acute exacerbations will be required in order to relate these findings to the disease condition itself. The presence of bronchiectasis, 19 nutritional status, 20 as well as previous use of antibiotics 21 can influence the type and frequency of colonization of the airways in COPD. Remarkably, the incidence of positive sputum cultures in half of our patient population was quite similar to previous data. 2,10,14,15 In exacerbated outpatients, prevalence of positive bacterial cultures, obtained by protected specimen brush, was 51.6%. 10 In a bronchoscopic study of 54 mechanically ventilated patients with acute exacerbation of COPD, bacterial infection was found in 50% of patients. 14 In another study among mechanically ventilated patients using protected specimen brush, Fagon et al. 22 reported distal bronchial infection in 50% of patients during acute exacerbation. In a large study of 1016 in-patients with acute exacerbation respiratory infection was found in 47% of sputum cultures. 15 Therefore, it seems a consistent finding that bacterial infection is present in 50% of exacerbations, in hospital as well as in outpatient populations. However, it remains difficult to distinguish bacterial colonization of the lower airways from an actual bacterial infection. In a bronchoscopic study among 18 stable COPD patients, using protected specimen brush samples, Cabello et al. 11 found that the distal airways were colonized (defined as X10 2 cfu/ml) in 83% of COPD patients. Quantitative cultures of BAL samples in the same patient group remained negative in 88%, suggesting colonization rather than infection. In another study using protected specimen brush samples, Monso et al. 10 found positive cultures in 25% of stable COPD patients and 52% of exacerbated COPD patients. In the stable COPD patients, concentrations of bacteria were much lower, again indicating colonization instead of bacterial infection. Besides differences in quantity of isolated microorganisms, recent studies suggest differences in the level of inflammation in stable COPD patients as well as during exacerbations between both conditions of the presence of bacteria in the airways. Bresser et al. 23 demonstrated that persisting strains of H. influenzae induce a weaker inflammatory response than non-persisting strains, while the local airway inflammation in COPD patients clinically infected with H. influenzae is much more pronounced. 24 Sethi et al. 25 demonstrated that exacerbated chronic bronchitis patients with H. influenzae and M. catharralis isolated from sputum had increased airway inflammation when compared to pathogen-negative exacerbations. Other studies indicate that bacterial infection contributes significantly to the inflammatory process in the airways. In acute exacerbations of COPD associated with H. influenzae infection, an increase in sputum IL-8, TNF-a and neutrophil elastase was found in contrast to exacerbations without bacterial infection, indicating increased airway inflammation in the presence of H. influenzae. 26 This inflammatory process in the airway continues despite antibiotic and steroid therapy for exacerbations, as was demonstrated by unchanging sputum cell counts during the course of an exacerbation. 27 However, the possible role of bacterial infections in the pathogenesis of acute exacerbations is still incompletely understood. In the present study, the outcomes in terms of hospital stay or subsequent need for ICU admission were not related to the presence or the type of bacterial infections. Our findings are in line with the disputed role of antibiotics in the treatment of acute exacerbations. Studies concerning the effect of antibiotic treatment have shown either no benefit or minimal clinical benefit from antibiotic treatment. 7 Meta-analysis of randomized controlled clinical trials demonstrated a clinically unimportant improvement in patients receiving antibiotics. 28 A recently performed meta-analysis on antibiotic treatment in acute exacerbations concluded that patients with more severe exacerbations are more likely to benefit from antibiotic treatment. 29 A recent study in exacerbated outpatients by Adams et al. 9 demonstrated lower relapse rates in outpatients treated with antibiotics, compared to patients untreated with antibiotics, but even

7 776 K.H. Groenewegen, E.F.M. Wouters higher relapse rates in patients treated with Amoxicillin. These results indicate that type of antibiotics used to treat acute exacerbations have an impact on the failure rate. In this respect, it is interesting to compare exacerbations of COPD to ventilator-associated pneumonia (VAP), a combination of clinical parameters in mechanically ventilated patients, that is presumed to be caused by bacteria and treated with antibiotics. In a recent bronchoscopic study among VAP patients, using protected specimen brush and BAL samples, bacterial infection was not proven in 43% of patients and withholding antibiotics in these patients had no effect on outcomes. 30 In another bronchoscopic study of VAP patients, the bacterial burden was not correlated with inflammatory mediators or with patient outcome. 31 Some limitations of the present study need further discussion. Spontaneously expectorated sputum was used for microbiological sampling, in contrast to for example induced sputum or bronchoscopic sampling. The suitability of sputum samples to analyze bacterial infection is a matter of debate. Recently, a good concordance between the results of two sampling methods, valid sputum samples and quantitative protected specimen brush, was shown. 32 At present, especially in patients with severe COPD, spontaneously expectorated sputum seems a clinically reliable method to assess the presence and type of bacterial infections when other methods have to be avoided. The present study has not included data on viral infections or infections with atypical organisms like Chlamydia and Mycoplasma. The presence of viral infection and Mycoplasma and Chlamydia during COPD exacerbations has been evaluated in different studies. In an outpatient population of mild-tomoderate COPD exacerbations, incidence of Chlamydia pneumoniae was found to be 4%. 33 In a study of mechanically ventilated patients with acute exacerbations of COPD, an incidence of C. pneumoniae of 18% was found. 14 The same study found no evidence for Mycoplasma pneumoniae infection and an incidence of 16% for respiratory viruses. In a Turkish study of outpatients with acute exacerbation, incidence of C. pneumoniae was 22% and M. pneumoniae incidence was 6%. 34 So far, most studies concerning respiratory pathogens have been performed in either outpatient populations with mild exacerbation, or mechanically ventilated patients with severe exacerbations in an ICU setting. Neither of these populations can be considered representative for the majority of admissions for COPD exacerbations in a clinical setting, as in the present study. Therefore, the role of these non-bacterial pathogens in the pathogenesis of COPD exacerbations needs further exploration. The present study indicates that the role of bacterial infections in the complex pathogenesis of COPD exacerbations as well as its clinical significance needs further evaluation in the near future and cannot be restricted to the limited discussion of the role of antibiotic treatment in the management of these acute events in the clinical course of patients with acute exacerbations. Especially, the role of bacterial infections in relation to the local and systemic inflammatory response has to be unraveled. The impact of acute exacerbations on the socio-economic burden of this disease as well as on the health status of the individual patient urgently needs to prioritize acute exacerbations in order to better understand the natural course of COPD. References 1. Rutten-van Molken MPH, Postma MJ, van Genugten MLL, Joore MA, Leidl R, Jager JC. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999;93: Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1998;157: Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Marlen TK. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320: Gompertz S, Bayley DL, Hill SL, Stockley RA. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56: Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55: Murphy TF, Sethi S. Bacterial infection in chronic obsructive pulmonary disease. Am Rev Resp Dis 1992;46: Hirschmann JV. Do bacteria cause exacerbations of COPD? Chest 2000;118: Murphy TF, Sethi S, Niederman MD. The role of bacteria in exacerbations of COPD. Chest 2000;118: Adams SG, Melo J, Luther MS, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000;117: Monso E, Ruiz J, Manterola J, et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Resp Crit Care Med 1995;152: Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Resp J 1997;10: Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis. Relation

8 Bacterial Infections in patients 777 between bacterial etiology and lung function. Chest 1998;113: Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999;116: Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Resp Crit Care Med 1998;157: Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Resp Crit Care Med 1996;154: American Thoracic Society. Standards for the diagnosis, care of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1995;152:S Global initiative for chronic obstructive pulmonary disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report. 18. Isenberg HD, Baron EJ, Damato RF, et al. Recommendations for the isolation of bacteria from clinical specimens. In: Balows A, Hausler Jr WJ, Herrmann KL et al., editors. Manual of clinical microbiology. Washington, DC: American Society for Microbiology, p Pang JA, Cheng A, Chan HS, Poon D, French G. The bacteriology of bronchiectasis in Hong Kong investigated by protected catheter brush and bronchoalveolar lavage. Am Rev Resp Dis 1989;139(1): Niederman MS, Mantovani R, Schoch P, Papas J, Fein AM. Patterns and routes of tracheobronchial colonization in mechanically ventilated patients. The role of nutritional status in colonization of the lower airway by Pseudomonas species. Chest 1989;95: Vincent JL. Microbial resistance: lessons from the epic study. Intensive Care Med 2000;26:S Fagon J-Y, Chastre J, Trouillet J-L, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Resp Dis 1990;142: Bresser P, van Alphen L, Habets FJM, et al. Persisting Haemophilus influenzae strains induce lower levels of interleukin-6 and interleukin-8 in H292 lung epithelial cells than non-persisting strains. Eur Resp J 1997;10: Bresser P, Out T, van Alphen L, Jansen HM, Lutter R. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection. Am J Resp Crit Care Med 2000;162: Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000;118: Sethi S, Evans N, Wrona C, Murphy TF. Airway inflammation in COPD: effects of clinical status and bacterial infection. A815. ATS Downey D, Brockbank S, Ennis M, Elborn S. The effect of infective exacerbations on chronic obstructive pulmonary disease on sputum cell counts. A821. ATS Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: a metaanalysis. JAMA 1995;273: Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Int Med 2001;134(7): Bonten MJM, Bergmans DCJJ, Stobberingh EE, et al. Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use. Am J Resp Crit Care Med 1997;156: Froon AHM, Bonten MJM, Gaillard CA, et al. Prediction of clinical severity and outcome of ventilator-associated pneumonia. Am J Resp Crit Care Med 1998;158: Soler N, Torres A, Celis R, et al. Bronchial microbial patterns in non-severe exacerbations of COPD: a bronchoscopic study. A307. ATS Blasi F, Legnani D, Lombardo VM, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Resp J 1993;6: Mogulkoc N, Karakurt S, Isalska B, et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Resp Crit Care Med 1999;160:

The Importance of Appropriate Treatment of Chronic Bronchitis

The Importance of Appropriate Treatment of Chronic Bronchitis ...CLINICIAN INTERVIEW... The Importance of Appropriate Treatment of Chronic Bronchitis An interview with Antonio Anzueto, MD, Associate Professor of Medicine, University of Texas Health Science Center,

More information

Management of Acute Exacerbations

Management of Acute Exacerbations 15 Management of Acute Exacerbations Cenk Kirakli Izmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital Turkey 1. Introduction American Thoracic Society (ATS) and European Respiratory Society

More information

Sputum bacteriology in patients with acute exacerbations of COPD in Hong Kong

Sputum bacteriology in patients with acute exacerbations of COPD in Hong Kong Respiratory Medicine (2005) 99, 454 460 Sputum bacteriology in patients with acute exacerbations of COPD in Hong Kong Fanny W.S. Ko a, Tony K.C. Ng b, Thomas S.T. Li c, Joan P.C. Fok a, Michael C.H. Chan

More information

COPD guidelines in relation to infections: a critical analysis

COPD guidelines in relation to infections: a critical analysis All course materials, including the original lecture, are available as webcasts/podcasts at www.ers-educationorg pages/default. aspx?id=1339&idbrowse=47399 COPD guidelines in relation to infections: a

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright 2002 by the Massachusetts Medical Society VOLUME 347 A UGUST 15, 2002 NUMBER 7 NEW STRAINS OF BACTERIA AND EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

More information

Airway Bacterial Concentrations and Exacerbations of Chronic Obstructive Pulmonary Disease

Airway Bacterial Concentrations and Exacerbations of Chronic Obstructive Pulmonary Disease Airway Bacterial Concentrations and Exacerbations of Chronic Obstructive Pulmonary Disease Sanjay Sethi 1,2, Rohin Sethi 2, Karen Eschberger 2, Phyllis Lobbins 3, Xueya Cai 4, Brydon J. B. Grant 1,2, and

More information

IdentifyingRiskFactorsforAcuteExacerbationsofChronicObstructivePulmonaryDisease

IdentifyingRiskFactorsforAcuteExacerbationsofChronicObstructivePulmonaryDisease Global Journal of Medical Research: F Diseases Volume 18 Issue 5 Version 1.0 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Online ISSN: 2249-4618 & Print ISSN:

More information

Thorax Online First, published on August 23, 2006 as /thx

Thorax Online First, published on August 23, 2006 as /thx Thorax Online First, published on August 23, 2006 as 10.1136/thx.2005.056374 Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease

More information

The Role of Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease

The Role of Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease ...SYMPOSIUM PROCEEDINGS... The Role of Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease Robert E. Hillberg, MD Presentation Summary Chronic obstructive pulmonary disease (COPD)

More information

Antibiotic Guidance for Treatment of Acute Exacerbations of COPD (AECOPD) in Adults

Antibiotic Guidance for Treatment of Acute Exacerbations of COPD (AECOPD) in Adults Antibiotic Guidance for Treatment of Acute Exacerbations of COPD (AECOPD) in Adults Antibiotics are not recommended for all patients with AECOPD as bacterial infection is implicated in less than one-third

More information

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. 1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness

More information

ORIGINAL INVESTIGATION. Microbiologic Determinants of Exacerbation in Chronic Obstructive Pulmonary Disease

ORIGINAL INVESTIGATION. Microbiologic Determinants of Exacerbation in Chronic Obstructive Pulmonary Disease ORIGINAL INVESTIGATION Microbiologic Determinants of Exacerbation in Chronic Obstructive Pulmonary Disease Antoni Rosell, MD; Eduard Monsó, MD; Néstor Soler, MD; Ferràn Torres, MD; Joaquim Angrill, MD;

More information

Diagnosis of Ventilator- Associated Pneumonia: Where are we now?

Diagnosis of Ventilator- Associated Pneumonia: Where are we now? Diagnosis of Ventilator- Associated Pneumonia: Where are we now? Gary French Guy s & St. Thomas Hospital & King s College, London BSAC Guideline 2008 Masterton R, Galloway A, French G, Street M, Armstrong

More information

an inflammation of the bronchial tubes

an inflammation of the bronchial tubes BRONCHITIS DEFINITION Bronchitis is an inflammation of the bronchial tubes (or bronchi), which are the air passages that extend from the trachea into the small airways and alveoli. Triggers may be infectious

More information

Optimizing antibiotic selection in treating COPD exacerbations

Optimizing antibiotic selection in treating COPD exacerbations REVIEW Optimizing antibiotic selection in treating COPD exacerbations Attiya Siddiqi Sanjay Sethi Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Veterans Affairs Western

More information

C hronic obstructive pulmonary disease (COPD) is one of

C hronic obstructive pulmonary disease (COPD) is one of 589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See

More information

COPD exacerbation. Dr. med. Frank Rassouli

COPD exacerbation. Dr. med. Frank Rassouli Definition according to GOLD report: - «An acute event - characterized by a worsening of the patients respiratory symptoms - that is beyond normal day-to-day variations - and leads to a change in medication»

More information

Skin reactivity to autologous bacteria isolated from respiratory tract of patients with obstructive pulmonary disease

Skin reactivity to autologous bacteria isolated from respiratory tract of patients with obstructive pulmonary disease Skin reactivity to autologous bacteria 149 Original Article Skin reactivity to autologous bacteria isolated from respiratory tract of patients with obstructive pulmonary disease J. Halasa 1, M. Halasa

More information

(cilia) that help sweep away fluids and/or particles International Journal of Pharmaceutical Sciences and Research 2055

(cilia) that help sweep away fluids and/or particles International Journal of Pharmaceutical Sciences and Research 2055 IJPSR (2014), Vol. 5, Issue 5 (Research Article) Received on 29 November, 2013; received in revised form, 21 February, 2014; accepted, 16 April, 2014; published 01 May, 2014 EVALUATION OF EFFICACY AND

More information

COPD Treatable. Preventable.

COPD Treatable. Preventable. My COPD Action Plan Patient s Copy (Patient s Name) Date Canadian Respiratory COPD Treatable. Preventable. This is to tell me how I will take care of myself when I have a COPD flare-up. My goals are My

More information

ANWICU knowledge

ANWICU knowledge ANWICU knowledge www.anwicu.org.uk This presenta=on is provided by ANWICU We are a collabora=ve associa=on of ICUs in the North West of England. Permission to provide this presenta=on has been granted

More information

Chapter 10 Respiratory System J00-J99. Presented by: Jesicca Andrews

Chapter 10 Respiratory System J00-J99. Presented by: Jesicca Andrews Chapter 10 Respiratory System J00-J99 Presented by: Jesicca Andrews 1 Respiratory System 2 Respiratory Infections A respiratory infection cannot be assumed from a laboratory report alone; physician concurrence

More information

Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions?

Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions? Respiratory Medicine (2004) 98, 178 183 Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions? Maria Tsoumakidou, Nikolaos Tzanakis,

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

THE PHARMA INNOVATION - JOURNAL Acute exacerbation of chronic obstructive pulmonary disease, caused by viruses: the need of combined antiinfective

THE PHARMA INNOVATION - JOURNAL Acute exacerbation of chronic obstructive pulmonary disease, caused by viruses: the need of combined antiinfective Received: 19-11-2013 Accepted: 28-12-2013 ISSN: 2277-7695 CODEN Code: PIHNBQ ZDB-Number: 2663038-2 IC Journal No: 7725 Vol. 2 No. 11. 2014 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION

More information

H ospitalisation due to an exacerbation of chronic

H ospitalisation due to an exacerbation of chronic 713 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled

More information

AECOPD: Management and Prevention

AECOPD: Management and Prevention Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London

More information

The Role Of Antibiotics In Microbial Interactions Of Copd

The Role Of Antibiotics In Microbial Interactions Of Copd Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Public Health Theses School of Public Health January 2013 The Role Of Antibiotics In Microbial Interactions Of Copd Kimberly

More information

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized

More information

CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement

CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement Evidence-Based Assessment of Diagnostic Tests for Ventilator- Associated Pneumonia* Executive Summary Ronald F. Grossman, MD, FCCP; and Alan Fein, MD,

More information

Guideline for the Diagnosis and Management of COPD

Guideline for the Diagnosis and Management of COPD Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially

More information

Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease

Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease 29 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Bronchoscopic validation of the significance of purulence in severe exacerbations of chronic obstructive pulmonary disease Néstor Soler, Carlos Agustí, Joaquim

More information

Chronic Obstructive Pulmonary Disease (COPD) Measures Document

Chronic Obstructive Pulmonary Disease (COPD) Measures Document Chronic Obstructive Pulmonary Disease (COPD) Measures Document COPD Version: 3 - covering patients discharged between 01/10/2017 and present. Programme Lead: Jo Higgins Clinical Lead: Dr Paul Albert Number

More information

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms

COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and

More information

Francesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy

Francesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy COPD EXACERBATIONS Francesco Blasi Head Respiratory Medicine Section Cardio-Thoracic Department University of Milan, Italy COPD OUTCOMES Cazzola M et al. ERJ 2008 COPD AND CARDIOVASCULAR DISEASE Cumulative

More information

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What

More information

Antibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract infections in adults

Antibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract infections in adults International Journal of Infectious Diseases (2005) 9, 274 279 http://intl.elsevierhealth.com/journals/ijid Antibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract

More information

Utility of pneumococcal urinary antigen detection in diagnosing exacerbations in COPD patients

Utility of pneumococcal urinary antigen detection in diagnosing exacerbations in COPD patients Respiratory Medicine (2010) 104, 397e403 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Utility of pneumococcal urinary antigen detection in diagnosing exacerbations

More information

T he prevalence of chronic obstructive pulmonary

T he prevalence of chronic obstructive pulmonary 164 REVIEW SERIES COPD exacerbations? 1: Epidemiology G C Donaldson, J A Wedzicha... The epidemiology of exacerbations of chronic obstructive pulmonary disease (COPD) is reviewed with particular reference

More information

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They

More information

An Update in COPD John Hurst PhD FRCP

An Update in COPD John Hurst PhD FRCP An Update in COPD John Hurst PhD FRCP Reader in Respiratory Medicine / Honorary Consultant University College London / Royal Free London NHS Foundation Trust j.hurst@ucl.ac.uk What s new in COPD papers

More information

Hospital-acquired Pneumonia

Hospital-acquired Pneumonia Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired

More information

Antimicrobial Stewardship in Community Acquired Pneumonia

Antimicrobial Stewardship in Community Acquired Pneumonia Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory

More information

Community Acquired Pneumonia. Abdullah Alharbi, MD, FCCP

Community Acquired Pneumonia. Abdullah Alharbi, MD, FCCP Community Acquired Pneumonia Abdullah Alharbi, MD, FCCP A 68 y/ male presented to the ED with SOB and productive coughing for 2 days. Reports poor oral intake since onset due to nausea and intermittent

More information

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:

Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to: Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict

More information

Lecture Notes. Chapter 16: Bacterial Pneumonia

Lecture Notes. Chapter 16: Bacterial Pneumonia Lecture Notes Chapter 16: Bacterial Pneumonia Objectives Explain the epidemiology Identify the common causes Explain the pathological changes in the lung Identify clinical features Explain the treatment

More information

Dr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher

Dr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep

More information

COPD Challenge CASE PRESENTATION

COPD Challenge CASE PRESENTATION Chronic obstructive pulmonary disease (COPD) exacerbations may make up more than 10% of acute medical admissions [1], and they are increasingly recognised as a cause of significant morbidity and mortality

More information

Changes in bronchial inflammation during acute exacerbations of chronic bronchitis

Changes in bronchial inflammation during acute exacerbations of chronic bronchitis Eur Respir J 21; 17: 1112 1119 Printed in UK all rights reserved Copyright ERS Journals Ltd 21 European Respiratory Journal ISSN 93-1936 Changes in bronchial inflammation during acute exacerbations of

More information

COPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS

COPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS IN THE NAME OF GOD COPD Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS Definition of COPD* COPD is a preventable and treatable chronic lung disease characterized by airflow limitation that is not fully

More information

JMSCR Vol 06 Issue 08 Page August 2018

JMSCR Vol 06 Issue 08 Page August 2018 www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i8.09 Original Article Sputum Bacteriology

More information

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam

More information

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH

More information

COPD: A Renewed Focus. Disclosures

COPD: A Renewed Focus. Disclosures COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss

More information

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015

Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong

More information

Session Guidelines. This is a 15 minute webinar session for CNC physicians and staff

Session Guidelines. This is a 15 minute webinar session for CNC physicians and staff Respiratory Disease Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and coding

More information

The Bacteriology of Bronchiectasis in Australian Indigenous children

The Bacteriology of Bronchiectasis in Australian Indigenous children The Bacteriology of Bronchiectasis in Australian Indigenous children Kim Hare, Amanda Leach, Peter Morris, Heidi Smith-Vaughan, Anne Chang Presentation outline What is bronchiectasis? Our research at Menzies

More information

Risk factors for lower airway bacterial colonization in chronic bronchitis

Risk factors for lower airway bacterial colonization in chronic bronchitis Eur Respir J 1999; 13: 338±342 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Risk factors for lower airway bacterial colonization in chronic

More information

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh

Bronchiectasis Domiciliary treatment. Prof. Adam Hill Royal Infirmary and University of Edinburgh Bronchiectasis Domiciliary treatment Prof. Adam Hill Royal Infirmary and University of Edinburgh Plan of talk Background of bronchiectasis Who requires IV antibiotics Domiciliary treatment Results to date.

More information

CCLI. Bronchiectasis Treatment Antibiotics. Charles Haworth. Physician / Patient Conference, Georgetown University, May 2017

CCLI. Bronchiectasis Treatment Antibiotics. Charles Haworth. Physician / Patient Conference, Georgetown University, May 2017 Physician / Patient Conference, Georgetown University, May 2017 Bronchiectasis Treatment Antibiotics Charles Haworth CCLI Cambridge Centre for Lung Infection Disclosures Educational talks and / or consultancy

More information

Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD

Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD Eur Respir J 2009; 34: 1066 1071 DOI: 10.1183/09031936.00195608 CopyrightßERS Journals Ltd 2009 Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD M. Miravitlles*, A. Marín #,

More information

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton

Life-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary

More information

COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic

COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic COPD: From Hospital to Home October 5, 2015 Derek Linderman, MD Associate Professor COPD Center Pulmonary Nodule Clinic Learning Objectives Know the adverse effects of COPD exacerbations Know mainstays

More information

HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY

HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health

More information

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation : The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone

More information

Newer fluoroquinolones in the treatment of acute exacerbations of COPD

Newer fluoroquinolones in the treatment of acute exacerbations of COPD REVIEW Newer fluoroquinolones in the treatment of acute exacerbations of COPD Amit Patel Robert Wilson Royal Brompton Hospital, London UK Abstract: Acute exacerbations of COPD are a major cause of morbidity

More information

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,

More information

ORIGINAL RESEARCH ARTICLE. A. Mirici, M. Meral and M. Akgun. Abstract

ORIGINAL RESEARCH ARTICLE. A. Mirici, M. Meral and M. Akgun. Abstract ORIGINAL RESEARCH ARTICLE Clin Drug Invest 2003; 23 (1): 55-62 1173-2563/03/0001-0055/$230.00/0 Adis International Limited. All rights reserved. Comparison of the Efficacy of Nebulised Budesonide with

More information

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university

What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent

More information

The McMaster at night Pediatric Curriculum

The McMaster at night Pediatric Curriculum The McMaster at night Pediatric Curriculum Community Acquired Pneumonia Based on CPS Practice Point Pneumonia in healthy Canadian children and youth and the British Thoracic Society Guidelines on CAP Objectives

More information

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease

More information

Lecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)

Lecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features

More information

Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center

Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Charles Krasner, M.D. University of NV, Reno School of Medicine Sierra NV Veterans Affairs Medical Center Kathy Peters is a 63 y.o. patient that presents to your urgent care office today with a history

More information

POLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS

POLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS POLICY F TREATMENT OF LOWER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: The Drugs & Therapeutics Committee Date: July 2018 Implementation

More information

Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012

Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012 Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012 INTRODUCTION PNEUMOTHORAX HEMOPTYSIS RESPIRATORY FAILURE Cystic Fibrosis Autosomal Recessive Genetically

More information

Page 126. Type of Publication: Original Research Paper. Corresponding Author: Dr. Rajesh V., Volume 3 Issue - 4, Page No

Page 126. Type of Publication: Original Research Paper. Corresponding Author: Dr. Rajesh V., Volume 3 Issue - 4, Page No ISSN- O: 2458-868X, ISSN P: 2458 8687 Index Copernicus Value: 49. 23 PubMed - National Library of Medicine - ID: 101731606 SJIF Impact Factor: 4.956 International Journal of Medical Science and Innovative

More information

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital

Turning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe

More information

PULMONARY EMERGENCIES

PULMONARY EMERGENCIES EMERGENCIES I. Pneumonia A. Bacterial Pneumonia (most common cause of a focal infiltrate) 1. Epidemiology a. Accounts for up to 10% of hospital admissions in the U.S. b. Most pneumonias are the result

More information

Respiratory Medicine. Some pet peeves and other random topics. Kyle Perrin

Respiratory Medicine. Some pet peeves and other random topics. Kyle Perrin Respiratory Medicine Some pet peeves and other random topics Kyle Perrin Overview 1. Acute asthma Severity assessment and management 2. Acute COPD NIV and other management 3. Respiratory problems in the

More information

The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis

The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis ERJ Express. Published on August 9, 2006 as doi: 10.1183/09031936.06.00074605 The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis Davies G +, Wells AU*, Doffman S

More information

HQO s Episode of Care for Chronic Obstructive Pulmonary Disease

HQO s Episode of Care for Chronic Obstructive Pulmonary Disease HQO s Episode of Care for Chronic Obstructive Pulmonary Disease Dr. Chaim Bell, MD PhD FRCPC Ontario Hospital Association Webcast October 23, 2013 Objectives 1. Describe the rationale and methodology for

More information

Background. Background. Background 3/14/2014. Conflict of Interest Statement:

Background. Background. Background 3/14/2014. Conflict of Interest Statement: Platform Presentations Comparison of zolpidem to other drugs associated with falls in hospitalized patients Ed Rainville, MSPharm. Conflict of Interest Statement: The speaker has no conflict of interest

More information

Integrated Cardiopulmonary Pharmacology Third Edition

Integrated Cardiopulmonary Pharmacology Third Edition Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive

More information

JMSCR Vol 04 Issue 12 Page December 2016

JMSCR Vol 04 Issue 12 Page December 2016 www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v4i12.124 COPD: Microbial Pattern in Acute Exacerbation

More information

Community Acquired & Nosocomial Pneumonias

Community Acquired & Nosocomial Pneumonias Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP

More information

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น

รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines

More information

Influenza Vaccine for Egyptian Elderly Patients with Chronic Obstructive Pulmonary Disease

Influenza Vaccine for Egyptian Elderly Patients with Chronic Obstructive Pulmonary Disease imedpub Journals http://www.imedpub.com/ Influenza Vaccine for Egyptian Elderly Patients with Chronic Obstructive Pulmonary Disease Hend M Taha Amira H Mahmoud and WalaaW Aly Geriatrics and Gerontology

More information

Acute exacerbations of chronic obstructive

Acute exacerbations of chronic obstructive Eur Respir Rev 2005; 14: 95, 78 82 DOI: 10.1183/09059180.05.00009507 CopyrightßERSJ Ltd 2005 Modulation of airway inflammation to prevent exacerbations of COPD M. Solèr ABSTRACT: Exacerbations of chronic

More information

NON-CF BRONCHIECTASIS IN ADULTS

NON-CF BRONCHIECTASIS IN ADULTS Séminaire de Pathologie Infectieuse Jeudi 25 juin 2008 Cliniques Universitaires UCL de Mont-Godinne, Yvoir NON-CF BRONCHIECTASIS IN ADULTS Dr Robert Wilson Royal Brompton Hospital, London, UK Aetiology

More information

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking

More information

Online Data Supplement. Impulse Oscillometry in Adults with Bronchiectasis

Online Data Supplement. Impulse Oscillometry in Adults with Bronchiectasis Online Data Supplement Impulse Oscillometry in Adults with Bronchiectasis Wei-jie Guan *1, Ph. D.; Yong-hua Gao *2, Ph. D.; Gang Xu *3, Ph. D.; Zhi-ya Lin 1, Ph. D.; Yan Tang 1, M. D.; Hui-min Li 1, M.

More information

Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe

More information

Key words: chronic bronchitis; COPD; cost; exacerbation; failure; pharmacoeconomics; primary care; treatment

Key words: chronic bronchitis; COPD; cost; exacerbation; failure; pharmacoeconomics; primary care; treatment Pharmacoeconomic Evaluation of Acute Exacerbations of Chronic Bronchitis and COPD* Marc Miravitlles, MD; Cristina Murio, MD; Tina Guerrero, BSt; and Ramon Gisbert, PhD; for the DAFNE Study Group Background:

More information

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC

Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease

More information

Is Acute Exacerbation of COPD (AECOPD) Related to Viral Infection Associated with Subsequent Mortality or Exacerbation Rate? KHERAD, Omar, et al.

Is Acute Exacerbation of COPD (AECOPD) Related to Viral Infection Associated with Subsequent Mortality or Exacerbation Rate? KHERAD, Omar, et al. Article Is Acute Exacerbation of COPD (AECOPD) Related to Viral Infection Associated with Subsequent Mortality or Exacerbation Rate? KHERAD, Omar, et al. Abstract There is a growing interest in better

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

CARE OF THE ADULT COPD PATIENT

CARE OF THE ADULT COPD PATIENT CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The

More information

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation

Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease

More information